# Diadema Partners LP 13F holdings Q2 2026: $791 million

Diadema Partners LP reported $791 million in 13F securities across 149 positions for the quarter ended June 30, 2026, in a holdings report filed August 14, 2026. Its largest holding was Viking Therapeutics Inc at $47.6 million, 6.0% of the reported value. Since Q1 2026 it opened 69 new positions and exited 64.

SpecStream is the live web data engine for teams and agents. It reads the SEC's Form 13F data sets each quarter, and this page is that reading, keyed on the manager's CIK and the security's CUSIP. Ask for the managers or the holdings you track, and each new 13F filing arrives in your sheet, CRM, Slack or agent as the SEC publishes it.

- Quarter: Q2 2026, the quarter ended June 30, 2026
- Reported value: $791,347,834
- Positions: 149
- Filed: August 14, 2026
- Report type: 13F holdings report
- CIK: 2026172
- Form 13F file number: 028-25172
- CRD number: 331527
- Business address: 2140 Headquarters Plaza East Tower, 2nd Floor, Morristown, NJ 07960
- SEC filing: [0001892688-26-000119](https://www.sec.gov/Archives/edgar/data/2026172/000189268826000119/0001892688-26-000119-index.htm)
- Investment adviser record: [Form ADV on SpecStream](https://specstream.ai/data/investment-advisers/firm/diadema-partners-lp-331527)

## Top 25 holdings by value

The largest of 149 positions by reported value at the end of the quarter ended June 30, 2026. Put and call options are marked in the class. Change is in shares or principal against the filing for the quarter ended March 31, 2026.

| Issuer | Class | Shares or principal | Value | Change since Q1 2026 |
| --- | --- | --- | --- | --- |
| Viking Therapeutics Inc | COM (call) | 1,220,800 | $47.6 million | +561,600 |
| Abivax SA | SPONSORED ADS (call) | 349,200 | $46.5 million | +249,200 |
| Bristol-Myers Squibb Co | COM (call) | 600,000 | $34.6 million | New |
| Abivax SA | SPONSORED ADS (put) | 252,400 | $33.6 million | +152,400 |
| [United Therapeutics Corp Del](https://specstream.ai/data/institutional-holders/united-therapeutics-corp-del-91307c102) | COM | 52,989 | $28.7 million | +25,686 |
| [Revolution Medicines Inc](https://specstream.ai/data/institutional-holders/revolution-medicines-inc-76155x100) | COM | 139,218 | $26.1 million | +58,346 |
| [Abivax SA](https://specstream.ai/data/institutional-holders/abivax-sa-00370m103) | SPONSORED ADS | 163,644 | $21.6 million | +87,700 |
| [Cogent Biosciences Inc](https://specstream.ai/data/institutional-holders/cogent-biosciences-inc-19240q201) | COM | 493,664 | $19.1 million | +170,900 |
| Bristol-Myers Squibb Co | COM (put) | 330,600 | $19 million | New |
| [Bridgebio Pharma Inc](https://specstream.ai/data/institutional-holders/bridgebio-pharma-inc-10806xaj1) | NOTE 1.750% 3/0 (principal) | 250,000 | $18.6 million | New |
| Corcept Therapeutics Inc | COM (call) | 206,300 | $17.9 million | +47,800 |
| [Biomarin Pharmaceutical Inc](https://specstream.ai/data/institutional-holders/biomarin-pharmaceutical-inc-09061g101) | COM | 312,846 | $17.9 million | +164,617 |
| [Viking Therapeutics Inc](https://specstream.ai/data/institutional-holders/viking-therapeutics-inc-92686j106) | COM | 441,808 | $17.2 million | -83,373 |
| Kymera Therapeutics Inc | COM (call) | 149,700 | $17.2 million | New |
| Novartis AG | SPONSORED ADR (put) | 100,000 | $15.7 million | New |
| Uniqure NV | SHS (put) | 299,000 | $13.8 million | No change |
| Viking Therapeutics Inc | COM (put) | 350,500 | $13.7 million | New |
| Biogen Inc | COM (call) | 60,000 | $13 million | New |
| Capricor Therapeutics Inc | COM NEW (put) | 534,400 | $12.9 million | -89,000 |
| Summit Therapeutics Inc | COM (call) | 860,200 | $12.5 million | New |
| Eli Lilly & Co | COM (put) | 10,000 | $12 million | New |
| Incyte Corp | COM (put) | 105,400 | $11.9 million | No change |
| [Edgewise Therapeutics Inc](https://specstream.ai/data/institutional-holders/edgewise-therapeutics-inc-28036f105) | COM | 272,214 | $11.1 million | New |
| Uniqure NV | SHS (call) | 235,400 | $10.8 million | -14,600 |
| Biontech Se | SPONSORED ADS (call) | 100,000 | $9.3 million | New |

## New positions in Q2 2026

69 positions not in the filing for the quarter ended March 31, 2026. The 25 largest are shown.

| Issuer | Class | Shares or principal | Value |
| --- | --- | --- | --- |
| Bristol-Myers Squibb Co | COM (call) | 600,000 | $34.6 million |
| Bristol-Myers Squibb Co | COM (put) | 330,600 | $19 million |
| [Bridgebio Pharma Inc](https://specstream.ai/data/institutional-holders/bridgebio-pharma-inc-10806xaj1) | NOTE 1.750% 3/0 (principal) | 250,000 | $18.6 million |
| Kymera Therapeutics Inc | COM (call) | 149,700 | $17.2 million |
| Novartis AG | SPONSORED ADR (put) | 100,000 | $15.7 million |
| Viking Therapeutics Inc | COM (put) | 350,500 | $13.7 million |
| Biogen Inc | COM (call) | 60,000 | $13 million |
| Summit Therapeutics Inc | COM (call) | 860,200 | $12.5 million |
| Eli Lilly & Co | COM (put) | 10,000 | $12 million |
| [Edgewise Therapeutics Inc](https://specstream.ai/data/institutional-holders/edgewise-therapeutics-inc-28036f105) | COM | 272,214 | $11.1 million |
| Biontech Se | SPONSORED ADS (call) | 100,000 | $9.3 million |
| Novartis AG | SPONSORED ADR (call) | 50,000 | $7.8 million |
| [4d Molecular Therapeutics in](https://specstream.ai/data/institutional-holders/4d-molecular-therapeutics-in-35104e100) | COM | 571,107 | $7.6 million |
| Hims & Hers Health Inc | COM CL A (call) | 200,000 | $6.9 million |
| Hims & Hers Health Inc | COM CL A (put) | 193,700 | $6.7 million |
| Royalty Pharma PLC | SHS CLASS A (call) | 100,000 | $5.6 million |
| Bioage Labs Inc | COM (call) | 200,100 | $4.9 million |
| Tenax Therapeutics Inc | COM NEW (call) | 307,000 | $4.5 million |
| [Relay Therapeutics Inc](https://specstream.ai/data/institutional-holders/relay-therapeutics-inc-75943r102) | COM | 230,677 | $4.3 million |
| TG Therapeutics Inc | COM (call) | 75,700 | $4.2 million |
| Monte Rosa Therapeutics Inc | COM (call) | 170,100 | $4.1 million |
| Arcus Biosciences Inc | COM (call) | 124,000 | $3.8 million |
| Unicycive Therapeutics Inc | COM NEW (call) | 792,600 | $3.7 million |
| Amgen Inc | COM (call) | 10,000 | $3.6 million |
| [Taysha Gene Therapies Inc](https://specstream.ai/data/institutional-holders/taysha-gene-therapies-inc-877619106) | COM SHS | 522,619 | $3.6 million |

## Positions exited in Q2 2026

64 positions in the filing for the quarter ended March 31, 2026 and not in this one, with the shares and value reported then. The 25 largest are shown.

| Issuer | Class | Shares or principal | Value |
| --- | --- | --- | --- |
| Vertex Pharmaceuticals Inc | COM (call) | 93,100 | $41.6 million |
| Liquidia Corporation | COM NEW (call) | 662,100 | $25 million |
| United Therapeutics Corp Del | COM (call) | 40,200 | $23.8 million |
| Apogee Therapeutics Inc | COM (call) | 222,500 | $18.7 million |
| [Bridgebio Pharma Inc](https://specstream.ai/data/institutional-holders/bridgebio-pharma-inc-10806xaj1) | NOTE 1.750% 3/0 | 250,000 | $18.6 million |
| Revolution Medicines Inc | COM (put) | 125,500 | $12.2 million |
| Merck & Co Inc | COM (put) | 100,000 | $12 million |
| United Therapeutics Corp Del | COM (put) | 20,000 | $11.9 million |
| [Jazz Pharmaceuticals PLC](https://specstream.ai/data/institutional-holders/jazz-pharmaceuticals-plc-g50871105) | SHS USD | 54,755 | $10.4 million |
| Terns Pharmaceuticals Inc | COM | 181,752 | $9.6 million |
| Roivant Sciences LTD | SHS (put) | 335,800 | $9.3 million |
| [Incyte Corp](https://specstream.ai/data/institutional-holders/incyte-corp-45337c102) | COM | 78,029 | $7.3 million |
| [TG Therapeutics Inc](https://specstream.ai/data/institutional-holders/tg-therapeutics-inc-88322q108) | COM | 206,928 | $6.9 million |
| Edgewise Therapeutics Inc | COM (call) | 212,500 | $6.7 million |
| [Bridgebio Pharma Inc](https://specstream.ai/data/institutional-holders/bridgebio-pharma-inc-10806x102) | COM | 85,311 | $6.3 million |
| Structure Therapeutics Inc | SPONSORED ADS (put) | 127,500 | $6.1 million |
| [Eli Lilly & Co](https://specstream.ai/data/institutional-holders/eli-lilly-co-532457108) | COM | 6,000 | $5.5 million |
| [Abbvie Inc](https://specstream.ai/data/institutional-holders/abbvie-inc-00287y109) | COM | 24,058 | $5.2 million |
| Crispr Therapeutics AG | NAMEN AKT (call) | 106,300 | $5.1 million |
| [Structure Therapeutics Inc](https://specstream.ai/data/institutional-holders/structure-therapeutics-inc-86366e106) | SPONSORED ADS | 72,234 | $3.5 million |
| Cytokinetics Inc | COM NEW (call) | 50,000 | $3.3 million |
| [Tenax Therapeutics Inc](https://specstream.ai/data/institutional-holders/tenax-therapeutics-inc-88032l605) | COM NEW | 179,738 | $2.9 million |
| [Capricor Therapeutics Inc](https://specstream.ai/data/institutional-holders/capricor-therapeutics-inc-14070b309) | COM NEW | 78,851 | $2.4 million |
| [Eyepoint Inc](https://specstream.ai/data/institutional-holders/eyepoint-inc-30233g209) | COM NEW | 178,545 | $2.3 million |
| [Climb Bio Inc](https://specstream.ai/data/institutional-holders/climb-bio-inc-28658r106) | COM | 286,126 | $2 million |

## Also on SpecStream

- [Diadema Partners LP Form 13F filing on EDGAR](https://www.sec.gov/Archives/edgar/data/2026172/000189268826000119/0001892688-26-000119-index.htm)
- [Diadema Partners LP investment adviser record (Form ADV)](https://specstream.ai/data/investment-advisers/firm/diadema-partners-lp-331527)
- [Largest 13F filers in New Jersey](https://specstream.ai/data/institutional-holdings/state/new-jersey)
- [Largest institutional managers by 13F value](https://specstream.ai/data/institutional-holdings)
- [Most widely held securities in 13F filings](https://specstream.ai/data/institutional-holders)

Source: [the SEC's Form 13F data sets](https://www.sec.gov/data-research/sec-markets-data/form-13f-data-sets). Public data published by the US Securities and Exchange Commission (US government work). Managers report these holdings themselves in Form 13F, and the SEC does not check or guarantee them. Form 13F lists long positions in US listed equities, some options and convertible notes held at the end of the quarter, and leaves out short positions, cash, most bonds and holdings below the reporting threshold. Values are market values in US dollars as the manager filed them. A manager can ask the SEC to keep some positions confidential for a time. This page uses SEC data and is not endorsed or certified by the SEC.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in Morristown, New Jersey

- [Software development companies in Morristown, New Jersey](https://specstream.ai/data/businesses/software-development-companies/morristown-new-jersey-united-states)
- [Insurance agencies in Morristown, New Jersey](https://specstream.ai/data/businesses/insurance-agencies/morristown-new-jersey-united-states)
- [Real estate firms in Morristown, New Jersey](https://specstream.ai/data/businesses/real-estate-firms/morristown-new-jersey-united-states)
- [Financial services firms in Morristown, New Jersey](https://specstream.ai/data/businesses/financial-services-firms/morristown-new-jersey-united-states)
- [Legal services firms in Morristown, New Jersey](https://specstream.ai/data/businesses/legal-services-firms/morristown-new-jersey-united-states)
- [Doctors' offices in Morristown, New Jersey](https://specstream.ai/data/businesses/doctors-offices/morristown-new-jersey-united-states)
